NPM1 and acute myeloid leukemia: However, poor clinical outcomes were collectively observed for NPM1-mutated MNs, with shorter median OS (20 months), as compared with those documented for NPM1 wild-type MNs (36.6 months) and NPM1-mutated AML (42.2 months) cases.